Among these, tirzepatide, a long-acting dual GLP-1R/GIPR agonist approved for diabetes and obesity, shows enhanced therapeutic outcomes on cardiometabolic diseases compared to selective GLP-1R agonists.20 Here, GIPR is linked to obesity disorder.